Comparison of systemic therapies used concurrently with radiation for the treatment of @entity1082 -associated XXXX .

@entity1 @entity3908 @entity137 @entity5 @entity3003 @entity900 @entity33 @entity1082
BACKGROUND: This was a retrospective study of @entity1 with @entity1082 )-associated @entity5 treated with concurrent systemic therapy and radiation. METHODS: Data were extracted through chart review, and statistical analyses included frequency tabulation, chi-square, and Kaplan-Meier tests. RESULTS: Three hundred thirty-nine @entity1 were analyzed; 166 received neoadjuvant chemotherapy. One hundred thirty-six @entity1 were treated with @entity900 , 123 with cetuximab, and 59 with @entity3003 . The 2-, 3-, and 5-year actuarial overall survival rates were 92%, 88%, and 78%, respectively. There were no significant differences in survival or disease control when analyzed by systemic agent. @entity3908 -treated @entity1 had greater hematologic @entity137 , and required more intravenous hydration. The incidence of confluent @entity33 was highest among @entity1 treated with cetuximab. CONCLUSION: Platin and cetuximab seem to have similar efficacy when delivered concurrently with radiation in our retrospective population study. Although @entity3908 did cause greater hematologic @entity137 , radiation-specific side effects seemed relatively comparable.    2015 Wiley Periodicals, Inc. Head Neck 38: E1554-E1561, 2016.
